NASDAQ:CTIC CTI BioPharma (CTIC) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free CTIC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock Analysis Get CTI BioPharma alerts: Email Address CTI BioPharma MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside1.0% Downside$9.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 starsMedical Sector913th out of 918 stocksPharmaceutical Preparations Industry399th out of 402 stocks 1.0 Analyst's Opinion Consensus RatingCTI BioPharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageCTI BioPharma has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CTIC. Previous Next 0.0 Dividend Strength Dividend YieldCTI BioPharma does not currently pay a dividend.Dividend GrowthCTI BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTIC. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for CTIC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added CTI BioPharma to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CTI BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of CTI BioPharma is held by insiders.Percentage Held by Institutions91.45% of the stock of CTI BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CTI BioPharma are expected to grow in the coming year, from ($0.25) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CTI BioPharma is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CTI BioPharma is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About CTI BioPharma Stock (NASDAQ:CTIC)CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CTIC Stock News HeadlinesFebruary 22, 2024 | investing.comConnect Biopharma Holdings Ltd (CNTB)December 16, 2023 | morningstar.comTheravance Biopharma Inc TBPHApril 18, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. October 23, 2023 | uk.investing.comCTI Engineering Co Ltd (9621)August 23, 2023 | stockhouse.comSEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider TradingJune 27, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi completes acquisition of CTI BioPharma Corp.June 26, 2023 | finance.yahoo.comSobi completes acquisition of CTI BioPharma Corp.June 7, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was upgraded to a Hold Rating at Stifel NicolausApril 18, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 30, 2023 | markets.businessinsider.comStifel Nicolaus upgrades CTI BioPharma (CTIC) to a HoldMay 25, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 25, 2023 | finance.yahoo.comSobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 24, 2023 | msn.comJMP Securities Maintains CTI BioPharma (CTIC) Market Perform RecommendationMay 24, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)May 16, 2023 | msn.comCTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go ThroughMay 16, 2023 | msn.comSVB Leerink Downgrades CTI BioPharma (CTIC)May 16, 2023 | markets.businessinsider.comSVB Securities downgrades CTI BioPharma (CTIC) to a HoldMay 16, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates CTI BioPharma Corp.May 15, 2023 | msn.comStifel Downgrades CTI BioPharma (CTIC)May 15, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for CTI BioPharmaMay 12, 2023 | msn.comNeedham Downgrades CTI BioPharma (CTIC)May 12, 2023 | msn.comUnusual Call Option Trade in CTI BioPharma (CTIC) Worth $312.39KMay 11, 2023 | reuters.comSweden's SOBI offers $1.7 bln to buy CTI BioPharmaMay 11, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CTI BioPharma Corp. BuyoutMay 11, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was downgraded to a Hold Rating at JMP SecuritiesMay 10, 2023 | msn.comCTI BioPharma shares soar 83% after Swedish Orphan Biovitrum announces $1.7 billion deal for the biotechMay 10, 2023 | msn.comCTI BioPharma Soars on $1.7B Acquisition by Orphan BiovitrumSee More Headlines Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2023Today4/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Price Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside-1.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Adam R. Craig M.B.A. (Age 57)M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director Comp: $1.09MMr. David H. Kirske (Age 69)Exec. VP, CFO & Sec. Comp: $590.41kMr. James K. Fong (Age 61)Exec. VP & Chief Commercial Officer Comp: $597.3kMr. Ed BellSr. Director of Investor RelationsMr. Bruce K. Bennett Jr. (Age 71)Sr. VP Global Pharmaceutical Operations Mr. John P. VolponeExec. VP & Chief of StaffDr. Jennifer A. SmithSr. VP of BiometricsMore ExecutivesKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHAbCellera BiologicsNASDAQ:ABCLKiniksa PharmaceuticalsNASDAQ:KNSAIronwood PharmaceuticalsNASDAQ:IRWDCollegium PharmaceuticalNASDAQ:COLLView All Competitors CTIC Stock Analysis - Frequently Asked Questions Should I buy or sell CTI BioPharma stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares. View CTIC analyst ratings or view top-rated stocks. What is CTI BioPharma's stock price target for 2024? 5 brokerages have issued 12-month target prices for CTI BioPharma's stock. Their CTIC share price targets range from $9.00 to $9.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests that the stock has a possible downside of 1.0%. View analysts price targets for CTIC or view top-rated stocks among Wall Street analysts. How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) released its quarterly earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company earned $21.08 million during the quarter, compared to the consensus estimate of $24.88 million. During the same period last year, the company earned ($0.38) earnings per share. When did CTI BioPharma's stock split? CTI BioPharma's stock reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is James A. Bianco's approval rating as CTI BioPharma's CEO? 8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN). This page (NASDAQ:CTIC) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingBiden’s $374B Giveaway Into This SectorDTIThe “Perfect Storm” for GoldGold Safe ExchangeBiden replacement revealed?Paradigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.